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Summary 1 
Previous research has identified insomnia as a predictor for the onset of depression. The aim 2 
of this meta-analysis is to investigate whether insomnia also predicts the onset of other mental 3 
disorders. Longitudinal studies were eligible for inclusion if they investigated insomnia at 4 
baseline (including nighttime- and daytime-symptoms) as a predictor of the later onset of 5 
psychopathology within a follow-up time-frame of at least 12 months. Thirteen primary 6 
studies were included. The results suggest that insomnia is a significant predictor for the onset 7 
of depression (10 studies, OR 2.83, CI 1.55-5.17), anxiety (6 studies, OR 3.23, CI 1.52-6.85), 8 
alcohol abuse (2 studies, OR 1.35, CI 1.08-1.67, and psychosis (1 study, OR 1.28, CI 1.03-9 
1.59). The overall risk of bias in the primary studies was moderate. This meta-analysis 10 
provides evidence that insomnia increases the risk for psychopathology. A future research 11 
agenda should include more prospective studies using established diagnostic criteria, 12 
assessing insomnia at baseline and including long-term follow-up intervals evaluating a wider 13 
range of mental disorders. In addition, prospective long-term interventional studies 14 
investigating the efficacy of insomnia treatment for the prevention of mental disorders are 15 
called for.  16 
 17 
Keywords: insomnia, sleep, psychopathology, depression, anxiety, prevention, risk factor 18 
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Abbreviations 1 
CBT-I, cognitive behavioral therapy for insomnia 2 
CI, confidence interval 3 
ICSD, international classification of sleep disorders 4 
OR, odds ratio 5 
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Introduction 1 
With a lifetime prevalence of around 25% of the overall population, mental disorders are 2 
highly prevalent [1]. Patients with mental disorders suffer from substantial impairments of 3 
quality of life and reduced ability to participate in professional and social life [2]. Around 35 4 
to 50% of patients with serious mental illness do not receive treatment in developed countries 5 
[3]. After onset of a mental disorder, there is often a delay of several years until first treatment 6 
is initiated [4]. In addition, among those who receive treatment, rates of nonresponse and 7 
relapse are relatively high: for major depression, for example, relapse rates after cognitive 8 
behavior therapy or antidepressant medication are around 50% [5,6]. 9 
For economic and practical reasons, it seems reasonable to implement preventive strategies 10 
predominantly in those at elevated risk for the onset of a mental disorder. Insomnia, a 11 
syndrome characterized by chronic sleep onset and/or sleep continuity problems associated 12 
with impairment of daytime functioning, has the potential to serve as an indicator for an 13 
elevated risk. Pathophysiologically, insomnia is associated with cognitive and physiological 14 
hyperarousal [7,8] increased pre-occupation with sleep [9] and maladaptive sleep-related 15 
behavior [10]. Insomnia has been identified as a predictor for the de-novo onset of major 16 
depression in two meta-analyses [11,12]. The effect sizes (odds ratios) found in these two 17 
meta analyses were 2.60 (95% CI: 1.98-3.42) and 2.27 (95% CI: 1.89-2.71). However, in 18 
these previous meta-analyses, some primary studies included participants with only nighttime 19 
symptoms without daytime symptoms, though daytime symptoms are a necessary requirement 20 
for the diagnosis of insomnia disorder. This is a limitation since in clinical practice, nighttime 21 
symptoms such as difficulties initiating and maintaining sleep are commonly reported, but do 22 
not require medical or psychological interventions in the absence of any daytime impairment. 23 
Clinical insomnia with daytime impairment, in contrast, is treated with either 24 
pharmacotherapy or psychotherapy [13]. Insomnia is also a frequent symptom of almost all 25 
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mental disorders [14]. Several studies indicate that insomnia may also be a risk factor for 1 
other psychiatric symptoms beyond depression, including anxiety and suicide [15]. 2 
This opens up the possibility to use treatment of insomnia for the prevention of mental 3 
disorders. Insomnia is well treatable, the first-line treatment being cognitive behavioral 4 
treatment for insomnia [16–18]. CBT-I is a treatment package including behavioral 5 
techniques, relaxation, and cognitive therapy. With CBT-I, insomnia symptoms can be 6 
significantly reduced in the short- and long-term [19]. As first step into prevention, the 7 
question whether insomnia predicts the later onset of different mental disorders has to be 8 
answered.  9 
To the best of our knowledge, no meta-analysis investigating insomnia, including daytime 10 
symptoms, as a potential risk factor for different psychiatric symptoms or disorders has yet 11 
been performed. The objective of the present study was to quantitatively summarize 12 
longitudinal studies investigating whether insomnia at baseline constitutes a risk factor for the 13 
later onset of a mental disorder.  14 
 15 
Methods 16 
The meta-analysis was performed in accordance with the recommendations of reporting for 17 
meta-analyses of observational studies in epidemiology [MOOSE, 20] and the PRISMA 18 
statement for reporting systematic reviews and meta-analyses of studies that evaluate health 19 
care interventions [21]. Two authors (TG and CK) independently performed the literature 20 
search, screened all titles and, where applicable, the abstracts and full texts of potentially 21 
eligible studies, and extracted relevant data for the analyses from the full texts of selected 22 
studies. Doubts were discussed together with the first and the last author (EH and CB) and 23 
resolved through decision by consensus.  24 
 25 
Search Strategy 26 
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The primary search was conducted from 1980 to March 2018. The following term was 1 
searched for in the abstract or title: (‘insomnia’) AND (various keywords for different mental 2 
disorders combined with ‘OR’, e.g. ’bipolar OR anxiety OR panic’, etc.) AND (‘longitudinal’ 3 
OR ‘epidemiolog*’ OR ‘prospective’ OR ‘risk factor’).  The literature search was performed 4 
using the databases PubMed, Medline, PsycInfo, and PsycArticles.  5 
In addition, for insomnia as a predictor of depression, eligible studies from our previous meta-6 
analysis [11] were included. Primary studies from Baglioni et al. [11] that did not meet 7 
inclusion criteria of the present meta-analysis, e.g. with regard to the definition of insomnia, 8 
were excluded from the present analysis.  The search period for this meta-analysis was from 9 
1980 to March 2010. To search for studies on depression published in the period between 10 
March 2010 and March 2018, we used the following search term: ‘insomnia’ AND 11 
‘depression’ AND ‘longitudinal’ OR ‘epidemiolog*’ OR ‘prospective’ OR ‘risk factor’. 12 
Appendix S1 reports the full information on the search strategy.  13 
Additional studies were searched by examining the reference lists of eligible publications and 14 
screening of recent congress abstracts (Congress of the European sleep research society and 15 
joint congress of the American academy of sleep medicine and the Sleep research society 16 
since 2014) for potentially eligible studies. Moreover, sleep researchers from the European 17 
Insomnia Network were contacted via e-mail to ask for ongoing research in this area. These 18 
strategies served to capture non-published literature.  19 
 20 
Study Selection 21 
 22 
The following inclusion criteria for primary studies were applied: 23 
- date: published between 1980 and March 2018. The lower time limit was selected 24 
because DSM III was published in 1980 and studies conducted before this date did not 25 
have the possibility to refer to modern definitions of mental disorders.  26 
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- language: published in English, Italian, German, Spanish or French language. 1 
- publication type: only primary studies were eligible, no reviews, meta-analyses, case 2 
reports, comments, or books. 3 
- age: studies only including participants with age > 18 at baseline  4 
- insomnia: Diagnosis of insomnia based on an interview or questionnaire covering both 5 
nighttime symptoms (such as sleep onset and sleep maintenance difficulties) as well as 6 
daytime symptoms (such as tiredness, reduced concentration and motivation) of the 7 
disorder. 8 
- mental disorders: Diagnosis of mental disorder based on DSM-III or a later version of 9 
DSM or ICD, verified via clinical interview or an abnormal score, exceeding the cutoff for 10 
pathology, in a validated self-rating questionnaire 11 
- baseline psychopathology: studies were included only if participants with indications of 12 
a mental disorder other than insomnia at baseline were excluded from the analysis or if the 13 
analyses in the primary study were statistically controlled for baseline psychopathology. 14 
- time span: only longitudinal studies with follow-up periods of at least 12 months were 15 
eligible. 16 
 17 
The authors of three primary studies were contacted per email because the data provided in 18 
their publications were not sufficient to calculate the parameters necessary for the meta-19 
analysis. Two of them responded and provided the missing details. 20 
  21 
Data Extraction 22 
 23 
The following variables were manually extracted from all included studies: publication year, 24 
number of participants at baseline and follow-up(s), number of follow-up measurements, time 25 
between baseline and last follow-up, inclusion and exclusion criteria, response rate, 26 
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confounding variables controlled for at baseline, mean age of participants, percentage of 1 
females in the sample, diagnostic process for insomnia andpsychopathology, odds ratio and 2 
corresponding 95% confidence intervals (measure of risk ratio for the onset of 3 
psychopathology for participants with insomnia compared to participants without insomnia). 4 
 5 
Meta-analytic calculations 6 
 7 
Meta-analyses examining the predictive value of presence of insomnia at baseline for 8 
presence of psychopathology at follow-up were performed for depression (n = 10), anxiety 9 
disorders (n = 6), alcohol abuse (n = 2), and psychotic disorders (n = 1) . Several studies were 10 
included with more than one outcome. As an exploratory analysis, a pooled effect size across 11 
all mental disorders was performed. If a primary study had more than one follow-up, the last 12 
follow-up was used for the analysis. The logarithms (logs) of the odds ratios (ORs) and their 13 
95% confidence intervals (CIs) were used for meta-analytic calculations. Assuming that there 14 
is a distribution of true effect sizes rather than a single true effect size, a random-effects model 15 
was selected for meta-analytic pooling of the primary studies [22]. As a test for heterogeneity, 16 
x
2
 tests and the I2 statistic derived from the x2 values were used. An alpha error < 0.20 and an 17 
I2 of at least 50% were taken as indicators of heterogeneity. Only in the absence of 18 
heterogeneity, it is recommended to use the fixed effects model, as it assumes that all studies 19 
share a common true effect size [22].  20 
 21 
Assessment of risk of bias 22 
The QUIPS (Quality in Prognosis Studies) Risk of Bias Assessment Instrument for Prognostic 23 
Factor Studies was used as a tool for the assessment of risk of bias in the individual studies 24 
[23]. The tool provides criteria for assessing risk of bias for each study on six dimensions: 25 
study participation, attrition, prognostic factor measurement, outcome measurement, 26 
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confounders, and statistical analysis. On the basis of predefined criteria, risk of bias is rated as 1 
low, medium or high. For the present study, the assessment tool was applied by two 2 
independent raters (TG and CK). After each rater had completed their work, results were 3 
compared and disagreements were resolved by discussion with a third rater (CB). Consensus 4 
could be reached for all judgements. Cronbach’s alpha was calculated as a measure of 5 
interrater reliability for the original grading of the two raters. Cronbach’s alpha can be 6 
interpreted as follows: > 0.7 acceptable reliability, >0.8 good reliability, > 0.9 excellent 7 
reliability.  8 
 9 
Publication Bias 10 
Furthermore, we tested for potential publication bias using funnel plots and Egger's tests [24]. 11 
They were created with the function funnel of the R package 'meta'. In a funnel plot, effect 12 
size (in this case, OR) is plotted against a measure of variability (standard error). The plot is 13 
usually asymmetrical in the case of publication bias. Egger's test is a statistical test for 14 
asymmetry of the funnel plot [24]. 15 
 16 
 17 
Results 18 
The process of study identification, screening for eligibility, and inclusion is shown in figure 19 
1.  20 
 21 
Please insert Figure 1 22 
 23 
 24 
 25 
Description of the sample 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
10 
 
Thirteen primary studies were included into the meta-analysis (table 1). The total sample 1 
(participants with and without insomnia) included 181,798 participants at baseline and 2 
133,967 at the last follow-up time points. Time between baseline and last follow-up was 61 3 
months on average, whereby 5 studies had their last follow-up after 12 months, three studies 4 
after 18 months, and the remaining studies had longer follow-up periods of up to 20 years.  5 
 6 
Please insert table 1  7 
[25–37] 8 
 9 
Main Results 10 
The results of the meta-analysis are shown in figure 2. The main result is that insomnia is a 11 
significant predictor for onset of depression (10 studies, OR 2.83, CI 1.55-5.17), anxiety (6 12 
studies, OR 3.23, CI 1.52-6.85), alcohol abuse (2 studies, OR 1.35, CI 1.08-1.67, and 13 
psychosis (1 study, OR 1.28, CI 1.03-1.59). In the exploratory analysis across all mental 14 
disorders, the model found an OR of 2.60 (CI: 1.70-3.97), indicating that primary insomnia is 15 
a significant predictor for later onset of psychopathology. Significant heterogeneity was 16 
present for depression, anxiety disorders, and the total sample.  17 
Due to this high heterogeneity, subgroup analyses were performed (Figure 3). Included 18 
studies were divided in those with a shorter follow-up duration (12-24 months) and a longer 19 
follow up duration (> 24 months). For both depression and anxiety outcomes, heterogeneity 20 
was nonsignificant in studies with shorter follow-up durations, but highly significant in 21 
studies with longer follow-ups. Insomnia as a predictor of mental disorders was significant for 22 
depression and anxiety in shorter follow-up studies and for anxiety in longer follow-up 23 
studies, but not for depression in longer follow-up studies.  24 
In addition, primary studies were divided in those including only participants free of any 25 
mental disorders at baseline (“pure” studies), and those allowing for comorbidity at baseline 26 
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and performing a statistical control. We found 11 “pure” studies and two with statistical 1 
control. Insomnia as a predictor of mental disorders remained significant in the sample of 11 2 
“pure” studies. Heterogeneity, however, was still significant in this subgroup.  3 
 4 
Please insert Figures 2 and 3 5 
 6 
Risk of bias 7 
Results of the risk of bias assessment, based on the QUIPS risk of bias assessment tool, are 8 
shown in table 2. The ratings are illustrated in three different colors, where green (happy 9 
smiley) indicates a low risk, orange (indifferent smiley) indicates a medium risk, and red (sad 10 
smiley) indicates a high risk. Interrater agreement (Cronbach’s alpha) was between 0.8 and 11 
1.0 for the six assessment dimensions. The risk of bias arising from the study samples (sample 12 
description, recruitment, inclusion and exclusion criteria) was rated as moderate for most 13 
studies. Deductions in the quality rating were given because several studies did not 14 
sufficiently describe the recruitment process and the criteria for participant inclusion. The 15 
most problematic aspect concerning risk of bias was study attrition, since most authors of 16 
primary studies did not make attempts to collect information on participants who dropped out. 17 
Concerning the prognostic factor and outcome measurement, the most frequent problem was 18 
that the handling of missing data (e.g. due to participants skipping questionnaire items) was 19 
not reported. Concerning confounding variables, we decided to include only primary studies 20 
with either ‘pure’ insomnia without comorbidity at baseline, or primary studies that 21 
documented comorbidity at baseline and statistically controlled for it. Thus, no primary study 22 
was rated as having a high risk of bias concerning confounders. However, most studies 23 
received the rating ‘moderate’ instead of ‘low’, e.g. because only a small range of potential 24 
confounders was assessed, or because the validity of the measurement was questionable. 25 
Finally, concerning the statistical analysis, risk of bias was rated as low for most studies.  26 
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 1 
Please insert table 2 2 
 3 
Publication bias 4 
Due to the small number of studies for the outcomes alcohol abuse (n=2) and psychotic 5 
disorders (n=1), funnel plots and Egger's tests were only created/computed for the outcomes 6 
depression and anxiety. The funnel plots are shown in Figure 4. Egger's tests were 7 
insignificant, indicating that funnel plots were not asymmetric, for both outcomes (depression: 8 
t = -1.192, p = 0.268; anxiety: t = -1.268, p = 0.274). However, visual inspection of the funnel 9 
plots indicated a certain degree of asymmetry, e.g. that publication bias cannot be excluded.  10 
 11 
Please insert Figure 4 12 
 13 
 14 
 15 
Discussion 16 
The present meta-analysis including 13 primary studies evaluated the predictive power of 17 
insomnia at baseline for the onset of a mental disorder within the follow-up period. We found 18 
that insomnia is a significant predictor for depression, anxiety, and alcohol abuse. One study 19 
suggested that insomnia is also a predictor of psychosis. This result remained significant when 20 
the analysis was limited to the 11 studies that only included participants without any mental 21 
comorbidity at baseline. Another subgroup analysis indicated that high levels of heterogeneity 22 
may be attributable to studies with very long follow-up durations (> 24 months), that may be 23 
biased due to maturation and history.  24 
 25 
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To our knowledge, the present study is the first meta-analysis investigating insomnia as a 1 
predictor of psychopathology in general. Our findings are in line with our previous meta-2 
analysis [11], which identified insomnia as a predictor of depression. The overall odds ratio 3 
for insomnia to predict depression was comparable with the previous publication (odds ratio 4 
2.10 and 2.8). In the present meta-analysis, we extended our previous finding [11], showing 5 
that the presence of insomnia at baseline also increased the odds of suffering from anxiety at 6 
follow-up. For the other investigated disorders (alcohol abuse, psychosis), the increase in risk 7 
was numerically slightly smaller (around factor 1.5) – however, this difference should not be 8 
over interpreted, since a statistical comparison between disorders was not performed. The 9 
funnel plots highlight that the results of the study by Chen et al. are outliers for depression as 10 
well as anxiety (much higher association between insomnia and mental disorders). A potential 11 
reason is that in the Chen et al. study, diagnoses were taken from medical records. Using 12 
medical records, compared to interviews or questionnaires that were used in the other studies, 13 
may potentially have led to an overdiagnosis of anxiety and depression, e.g. for accounting or 14 
invoicing reasons. Another potential reason is a difference in the insomnia diagnosis (ICD in 15 
the Chen et al. study vs. DSM or questionnaires in others).  16 
 17 
In the following paragraphs, different explanations for the association between insomnia and 18 
mental disorders will be discussed. The finding that insomnia is a risk factor not only for a 19 
specific mental disorder such as depression, but for a wide range of disorders, fits well with 20 
the basic idea of ‘Research Domain Criteria’ [RDOC, 38]. The RDoC authors propose that 21 
despite a high variability of observable symptoms, dysfunctions in only a limited number of 22 
neurobiological systems underly all or most mental disorders. The finding of the present 23 
meta-analysis highlights the importance of the RDoC domain ‘arousal’. Hyperarousal, 24 
manifesting itself e.g. in increased fast frequency EEG activity or an increased heart rate, is a 25 
known biomarker of insomnia [7,8]. Alterations in brain arousal states are also associated with 26 
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a number of mental disorders including depression, anxiety disorders, schizophrenia, 1 
borderline personality disorder, posttraumatic stress disorder, and addiction [39–41]. Specific 2 
interactions of genetic and environmental risk factors contribute to a brain arousal profile that 3 
is associated with an increased risk for mental disorders [42]. Most likely, insomnia plays an 4 
important part as a risk factor in this process. 5 
The neuroplasticity hypothesis also can, at least in part, explain how insomnia could 6 
contribute to depression. According to this hypothesis, a dysfunction of synaptic plasticity is a 7 
major pathomechanism of depression [43]. Synaptic plasticity is the neurobiological 8 
mechanism by which the brain adapts to learning tasks and an ever changing environment 9 
[44]. In short, synapses have the ability to increase or decrease their strength, based on 10 
previous activity patterns. Recent research has shown that synaptic plasticity is reduced in 11 
patients with acute major depressive disorder [45]. Sleep, in turn, promotes learning and 12 
neuroplasticity [46,47]. Taken together, insomnia, which results in chronic sleep restriction, 13 
may increase vulnerability for a dysfunction of neuroplasticity as a pathomechanism of 14 
depression.  15 
Another potential pathway is sleep’s role in emotion regulation. Sleep is important for basic 16 
emotional responses such as fear conditioning and fear extinction [48] and also impacts on 17 
more complex forms of emotional processing such as the discrimination of threatening and 18 
friendly faces [49] and response to reward [50]. Thus, chronic sleep deprivation in the form of 19 
insomnia disorder may impair adequate emotional processing and thus increase vulnerability 20 
for psychopathology. However, none of the theories mentioned explains very well why a 21 
subgroup of patients with insomnia does develop a mental disorder, but another substantial 22 
proportion does not.  23 
Compared to the association between insomnia and depression/anxiety, the association with 24 
alcohol abuse and psychosis was numerically smaller and, for alcohol abuse, less consistent 25 
(one significant and one insignificant result). This may be an incidental finding, since the 26 
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sample of primary studies was much smaller for alcohol abuse and psychosis. It may, 1 
however, also point to the fact that the nature of association between insomnia and different 2 
mental disorders is different. For example, alcohol use may, for some patients with insomnia, 3 
be a (dysfunctional) coping mechanism, since better sleep is often expected after the intake of 4 
alcoholic beverages the evening. In patients with a specific vulnerability for substance misuse, 5 
but not in the majority of patients with insomnia, this may result in alcohol abuse and 6 
dependency.  For psychosis, in contrast, the nature of the association may be on a more 7 
neurobiological level, e.g. mediated via a hyperactivity of the dopaminergic system that has 8 
been associated with both sleep difficulties and psychotic experiences [51]. 9 
In subgroup analyses, we investigated whether the association between insomnia and mental 10 
disorders is different for studies with short-term follow-up (12-24 months) and longer follow-11 
up duration (> 24 months). Interestingly, numerically, insomnia appeared to have a greater 12 
effect on short term depression than long term depression, but a greater effect on short term 13 
anxiety than long term anxiety. A likely explanation is that this is an artifact attributable to the 14 
Chen et al. study, which is an outlier. This study has a greater biasing effect on the long term 15 
anxiety outcome than the long term depression outcome, because there are only two studies 16 
investigating long term anxiety, but four investigating long term depression. 17 
The present meta-analysis has several strengths and limitations. An important characteristic of 18 
our study is that the presence of both daytime and nighttime symptoms of insomnia at 19 
baseline was required for the inclusion of primary studies into the meta-analysis. This is in 20 
line with current diagnostic criteria of insomnia [52,53]. Daytime symptoms of insomnia are 21 
heterogeneous and include tiredness, fatigue, reduced concentration and motivation, 22 
depressed or irritable mood as well as impaired functioning and quality of life. The 23 
background is that a diagnosis of insomnia should not be made in cases of mild sleep 24 
disturbances which do not lead to daytime impairment, or in cases of habitual short sleep, 25 
which is a normal variation rather than a disorder. Fifty-one studies were excluded because 26 
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they did not meet this criterion, i.e. the authors reported on sleep disturbances only and did 1 
not assess daytime symptoms. This finding points to the fact that daytime symptoms of 2 
insomnia are frequently neglected in the diagnostic process and treatment planning [54].  3 
 4 
Concerning the implementation of research findings into clinical practice, a limitation of this 5 
meta-analysis is that it demonstrates a temporal association between insomnia and 6 
psychopathology, but does not allow for causal attributions. If insomnia causally contributes 7 
to the onset of mental disorders, early treatment of insomnia would be likely to reduce the risk 8 
of later psychopathology. However, it cannot be excluded that insomnia is simply an early 9 
symptom which is not causally linked to the later onset or progress of a mental illness. In this 10 
case, early insomnia treatment would still be needed in order to alleviate the symptoms of 11 
insomnia itself - however, benefits in terms of prevention would be limited in this case. In an 12 
Australian clinical trial [55] patients with insomnia who did not meet criteria for major 13 
depression at baseline were randomized to CBT-I or a placebo intervention. In this trial, CBT-14 
I was delivered in the form of an online self-help program. At 6-month follow-up, the 15 
incidence rate of major depressive episode was not significantly different in the two groups. 16 
This lack of significant effect may be due to the low total incidence rate (4%), indicating that 17 
the follow-up period of 6 months may have been too short to display differences. An 18 
alternative explanation is that the intervention was too weak to have a preventive effect.   19 
CBT-I was more effective than the placebo in the reduction of subclinical depressive 20 
symptoms (i.e., subjects exhibiting some depressive symptoms, but not meeting criteria for 21 
major depressive disorder), suggesting that there is some kind of effect on psychopathology 22 
beyond the improvement of sleep quality. This important research question needs to be further 23 
clarified in interventional studies. 24 
 25 
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In conclusion, this meta-analysis provides evidence that insomnia increases the odds for the 1 
future onset of psychopathology. In our literature search, we found that previous research has 2 
focused on depression and anxiety, whereas research into other mental disorders is scarce. In 3 
addition, there is a shortage of longitudinal studies. A future research agenda should include 4 
more prospective studies with a thorough diagnostic procedure for insomnia (including 5 
daytime symptoms) at baseline and long (≥ 2 years) follow-up intervals assessing a wide 6 
range of psychopathology. In case of positive findings confirming the role of insomnia as a 7 
predictor of psychopathology, more interventional studies investigating the efficacy of 8 
insomnia treatment for the prevention of mental disorders are needed.  9 
 10 
Practice Points 11 
• Insomnia is a predictor for the future onset of depression, anxiety, and alcohol abuse, and 12 
a potential predictor of psychotic symptoms.  13 
• We recommend screening patients with insomnia for mental disorders. 14 
• In the diagnostic process for insomnia and mental disorders in research and clinical 15 
practice, we recommend to adhere to diagnostic criteria.  16 
•  17 
 18 
Research Agenda 19 
• Novel prospective research with long-term follow-up intervals evaluating insomnia 20 
diagnosis as a predictor of a wider range of mental disorders is called for. 21 
• More prospective clinical trials are needed to investigate whether early treatment of 22 
insomnia can prevent the onset of mental disorders. 23 
 24 
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Figure and Table legends  1 
 2 
Table 1 Characteristics of included studies 3 
BDI, Beck Depression Inventory; CIS-R, Clinical Interview Schedule revised; DIS, 4 
Diagnostic Interview Schedule (DSM-III) HADS, Hospital Anxiety and Depression Scale; 5 
HADS, Hospital Anxiety and Depression Scale; ISI, Insomnia Severity Index; PSQ, Psychosis 6 
Screening Questionnaire; SCAN, Schedule for Clinical Assessment in Neuropsychiatry; 7 
SPIKE, Structured Psychopathological Interview and Rating of Social Consequences of 8 
Psychic Disturbances for Epidemiology 9 
 10 
Table 2 Risk of Bias Assessment for included studies 11 
The QUIPS (Quality in Prognosis Studies) Risk of Bias Assessment Instrument for Prognostic 12 
Factor Studies was used as a tool for the assessment of risk of bias in the individual studies. 13 
This instrument was developed by a work group comprising epidemiologists, statisticians, and 14 
clinicians in 2013 [24]. The tool provides criteria for assessing risk of bias for each study on 15 
six dimensions: study participation, attrition, prognostic factor measurement, outcome 16 
measurement, confounders, and statistical analysis. 17 
 18 
Figure 1 Flow of the study search 19 
Flow of search process with study identification, abstract screening, assessment of eligibility 20 
and inclusion into the meta-analysis.  21 
 22 
Figure 2 Forest plot 23 
Summary of the meta-analysis for the predictive value of insomnia for future 24 
psychopathology. CI confidence interval, d effect size Cohen's d, OR odds ratio, se standard 25 
error. 26 
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 1 
Figure 3 Subgroup analyses 2 
CI confidence interval, d effect size Cohen's d, OR odds ratio, se standard error. 3 
A. Included primary studies were divided in those with a shorter follow-up duration (12-24 4 
months) and a longer follow up duration (> 24 months). 5 
B. Primary studies were divided in those including only participants free of any mental 6 
disorders at baseline (“pure”), and those allowing for comorbidity at baseline and 7 
performing a statistical control (“stat”). 8 
 9 
Figure 4 Funnel plots 10 
Funnel plots for the assessment of publication bias. Each dot represents one included study. 11 
Egger's tests were insignificant, indicating that funnel plots were not asymmetric (depression: 12 
t = -1.192, p = 0.268; anxiety: t = -1.268, p = 0.274). Vertical line indicates the pooled effect 13 
size; funnel indicates 95% confidence intervals.  14 
 15 
 16 
 17 
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Publication Insomnia  
diagnostic method 
definition of insomnia 
daytime symptoms 
Psychopathology 
diagnostic method 
last FU 
(months) 
sample N  
(baseline) 
N  
(last FU) 
Mean age % female 
Banovic et al. [25] ISI total score >14 according to ISI depression: HADS-D > 8  
anxiety: HADS-A > 8 
12 patients with Crohn’s 
disease 
57 52 41.2 ± 12.5 55.8 
Buysse et al. [26] clinical interview 
(DSM-IV criteria) 
according to clinical 
interview (DSM-IV) 
depression:SPIKE structured 
interview 
240 representative sample from 
Zürich, Switzerland 
591 275 20-21 n.r. 
Chen et al. [27]  ICD-9 diagnosis in 
medical records 
ICD-9 diagnosis in medical 
records 
depression and anxiety: ICD-9 
diagnoses in medical records 
48 population-based sample 
from Taiwan 
57819 57819 53.7±17.0 55.9 
Drake et al. [28]  questionnaire based 
on DSM-IV 
question on daytime 
interference, answered on 
4-point scale 
depression: QIDS total score ≥ 
11 
12 community-based sample 
from Michigan, USA 
2892 2316 n.r. n.r. 
Ford & Kamerow [29]  DIS (based o DSM-III) question about 
interference with life 
depression, anxiety, alcohol 
abuse: diagnosis according to 
DSM-III made in structured 
interview 
12 community-based sample 
from the USA 
10534 7954 n.r. 59.8 
Haario et al. [30]  four-item Jenkins 
Sleep Questionnaire 
feeling ‘ "tired and worn 
out" during day 
alcohol abuse:questionnaire on 
drinking habits based on Finnish 
Guideline 
84 40–60 
year-old employees from 
Helsinki, Finland 
8960 7332 40-60 80 
Jansson-Frojmark et 
al. [31]  
research diagnostic 
criteria DSM-IV-TR 
list of 10 daytime 
symptoms rated on 5-point 
scale 
depression: HADS-D > 8  
anxiety: HADS-A > 8 
18 general population from 
Sweden 
2333 1795 47·1 54.9 
Livingston et al. [32]  semi-structured 
inverview 
feeling tired or sleepy 
during the day 
depression:semi-structured 
inverview 
24 persons 65 years and older 
living at home in London 
705 524 n.r. 63.4 
Morphy et al.  [33] four-item Jenkins 
Sleep Questionnaire 
feeling ‘ "tired and worn 
out" during day 
depression: HADS-D > 8  
anxiety: HADS-A > 8 
12 random sample from five 
general practices in 
Staffordshire, UK 
2662 1589 51.7±17.5 55.9 
Sheaves et al. [34] CIS-R question about tiredness psychosis;SCAN interview 18 people aged 16 years and 
older in the UK 
2046 2046 43.9 53.2 
Sivertsen et al. [35]  questionnaire based 
on DSM-IV 
impaired work 
performance caused by 
insomnia during 
preceding year 
depression: HADS-D > 8 132 general population in 
Norway (HUNT study) 
43045 24715 45.3 56.9 
Sivertsen et al. [36]  questionnaire based 
on DSM-IV 
impaired work 
performance caused by 
insomnia during 
preceding year 
anxiety: HADS-A > 8 132 general population in 
Norway (HUNT study) 
43045 24715 45.3 56.9 
Suh et al. [37] short questionnaire feeling unrefreshed in the 
morning 
depression: BDI total score ≥ 16 72 community-based sample 
from Korea 
1282 1089 52.3±7.1 56 
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Table 2. Assessment of risk of bias based on the QUIPS risk of bias assessment tool 
 
Sample Attrition Prognostic Factor 
Measurement 
Outcome  
Measurement 
Confounders Statistics 
Banovic et al. [25]    ☺   
Buysse et al. [26] ☺   ☺   
Chen et al. [27]  ☺     ☺ 
Drake et al. [28]     ☺  ☺ 
Ford & Kamerow [29]  ☺   ☺  ☺ 
Haario et al. [30]      ☺  
Jansson-Frojmark et al. [31]     ☺  ☺ 
Livingston et al. [32]  ☺      
Morphy et al.  [33]      ☺ 
Sheaves et al. [34]    ☺   
Sivertsen et al. [35]     ☺  ☺ 
Sivertsen et al. [36]  ☺   ☺  ☺ 
Suh et al. [37]    ☺  ☺ 
Interrater reliability 
(Cronbach’s alpha) 0.9 1.0 0.8 1.0 1.0 1.0 
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Abstracts identified through database 
searching 
PsycInfo, PsycArticles, Medline: n=1176 
PubMed: n=810 
total number of abstracts= 1986 
 
Duplicate removal 
Duplicates: n=966 
abstracts after duplicate removal: 1020 
 
Full-text articles assessed for 
eligibility 
n = 102 
Studies included in meta analysis (n = 13) 
 Depression  (n = 10) 
 Anxiety disorders (n = 6) 
 Alcohol abuse (n = 2) 
 Psychotic disorders (n = 1) 
(some studies had more than one outcome) 
Reasons for abstract exclusion 
 type of publication (n = 238) 
 insomnia definition (n = 11) 
 mental disorder definition (n = 15) 
 no longitudinal design (n = 252) 
 no control for confounders  (n = 21) 
 last follow-up <12months (n = 77) 
 age <18 years (n = 75) 
 language (n = 1) 
 clinical trial/intervention (n = 187) 
 no control group (n = 19) 
 insomnia as outcome, not as predictor (n = 36) 
number of excluded abstracts= 932 
 
 
Additional records identified through 
other sources 
 Baglioni et al. 2011 meta analysis (n = 2) 
 references of eligible abstracts (n = 10) 
 congress abstracts (n = 2) 
total number of additional abstracts: 14 
Reasons for exclusion of fulltexts 
 insomnia definition (n = 40) 
 mental disorder definition (n = 5) 
 no longitudinal design (n = 3) 
 no control for confounders  (n = 4) 
 last follow-up <12months (n = 5) 
 age <18 years (n = 4) 
 clinical trial/intervention (n = 3) 
 no control group (n = 2) 
 insomnia as outcome, not as predictor (n = 11) 
 outcome: no mental disorder (n = 10) 
 data for odds ratio not available (n = 2) 
number of excluded fulltexts= 89 
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Random effects model
heterogeneity I2 = 96.19%, τ2 = 0.77, p < 0.01
Anxiety disorders  
Alcohol abuse      
Random effects model
Random effects model
Random effects model
heterogeneityI2 = 93.67%, τ2 = 0.79, p < 0.01
heterogeneityI2 = 96.37%, τ2 = 0.78, p < 0.01
heterogeneityI2 = 0%, τ2 = 0, p = 0.91
Study
Depression         
Banovic et al. [25] 
Buysse et al. [26] 
Chen et al. [27] 
Drake et al. [28] 
Ford & Kamerow [29] 
Jansson−F. et al. [31] 
Livingston et al. [32] 
Morphy et al. [33] 
Sivertsen et al. [35] 
Suh et al. [37]
Banovic et al. [25] 
Chen et al. [27] 
Ford & Kamerow [29] 
Jansson−F. et al. [31] 
Morphy et al. [33] 
Sivertsen et al. [36]
Haario et al. [30]  
Ford & Kamerow [29]
Psychotic disorders 
Sheaves et al. [34] 
Random effects model 
heterogeneity not applicable
d
1.58
0.47
2.16
1.15
0.47
1.30
1.17
1.52
0.28
0.52
2.03
2.17
0.41
0.85
1.14
0.73
0.29
0.34
0.25
se(d)
1.27
0.16
0.10
0.30
0.60
0.30
0.38
0.30
0.17
0.29
0.80
0.08
0.26
0.27
0.21
0.12
0.12
0.37
0.11
0.1 0.2 0.5 1 2 5 20
no insomnia insomnia OR
2.60
2.83
3.23
1.35
1.28
4.85
1.60
8.66
3.17
1.60
3.66
3.22
4.56
1.32
1.69
7.65
8.72
1.50
2.34
3.14
2.08
1.34
1.40
1.28
95%−CI
[1.70;  3.97]
[1.55;  5.17]
[1.52;  6.85]
[1.08;  1.67]
[1.03;  1.59]
[0.40; 59.01]
[1.16;  2.21]
[7.08; 10.59]
[1.78;  5.65]
[0.49;  5.21]
[2.04;  6.57]
[1.53;  6.78]
[2.52;  8.24]
[0.95;  1.83]
[0.95;  3.00]
[1.61; 36.45]
[7.50; 10.14]
[0.90;  2.50]
[1.39;  3.93]
[2.07;  4.75]
[1.63;  2.65]
[1.07;  1.68]
[0.68;  2.90]
[1.03;  1.59]
Weight
100.00%
50.70%
32.20%
11.12%
5.98%
1.95%
5.87%
5.99%
5.46%
4.13%
5.44%
5.11%
5.43%
5.86%
5.46%
3.33%
6.03%
5.58%
5.56%
5.74%
5.96%
5.97%
5.15%
5.98%
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Study
Random effects model
heterogeneityI2 = 96.37%, t2 = 0.78, p < 0.01
pure
Random effects model
heterogeneityI2 = 97.09%, t2 = 0.79, p < 0.01
stat
Banovic et al. [25] 
Random effects model 
heterogeneitynot applicable
Chen et al. [27]
Ford & Kamerow  [29] 
Jansson−F. et al. [31] 
Morphy et al. [33] 
Sivertsen et al. [36]
d
2.03
2.17
0.41
0.85
1.14
0.73
se(d)
0.80
0.08
0.26
0.27
0.21
0.12
0.1 0.2 0.5 1 2 5 20
no insomnia insomnia OR
3.23
7.65
2.92
7.65
8.72
1.50
2.34
3.14
2.08
95%−CI
[1.52;  6.85]
[1.61; 36.45]
[1.31;  6.51]
[1.61; 36.45]
[7.50; 10.14]
[0.90;  2.50]
[1.39;  3.93]
[2.07;  4.75]
[1.63;  2.65]
Weight
100.00%
10.39%
89.61%
10.39%
18.70%
17.33%
17.28%
17.82%
18.48%
Study
Random effects model
heterogeneityI2 = 96.37%, t2 = 0.78, p < 0.01
short
long 
Random effects model
Random effects model
heterogeneityI2 = 56.96%, t2 = 0.11, p = 0.07
heterogeneityI2 = 98.98%, t2 = 1.02, p < 0.01
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